International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

Leukemia

Volumn 21, Issue 5, 2007, Pages 956-964

  Rawstron, A C ^a   Villamor, N ^b   Ritgen, M ^c   Bottcher S ^c   Ghia, P ^d   Zehnder, J L ^e   Lozanski, G ^f   Colomer, D ^b   Moreno, C ^b   Geuna, M ^g   Evans, P A S ^a   Natkunam, Y ^f   Coutre, S E ^e   Avery, E D ^e   Rassenti, L Z ^h   Kipps, T J ^h   Caligaris Cappio, F ^d   Kneba, M ^c   Byrd, J C ^f   Hallek, M J ⁱ   Montserrat, E ^b   Hillmen, P ^a   more..

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; CD79B ANTIGEN; CD81 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; LEUKOSIALIN; PREDNISONE; VINCRISTINE;

ACCURACY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEAM THERAPY; BLOOD ANALYSIS; BONE MARROW; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE SURVEILLANCE; DRUG EFFICACY; FALSE POSITIVE RESULT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LABORATORY TEST; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 34247594390     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404584     Document Type: Article

References (23)

1. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:.6-14. E-pub 5 July 2002.
2. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU et al. German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-3120.
3. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G et al. German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-1101.
4. Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004; 45: 711-714.
5. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD et al. National Cancer Research Institute Haematological Studies Group. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397-404. E-pub 29 April 2004.
6. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2602. E-pub 17 June 2004.
7. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088. E-pub 14 Mar 2005.
8. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-4078. E-pub 14 March 2005.
9. Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. For the GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.Br J Haematol 2002; 119: 976-984.
10. Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.Blood 2001; 98 29-35.
11. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228-2235.
12. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979. E-pub 28 February 2005.
13. Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997; 11: 1909-1914.
14. Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195-204.
15. Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563-4569. E-pub 31 January 2006.
16. Bottcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637-1645.
17. Maloum K, Sutton L, Baudet S, Laurent C, Bonnemye P, Magnac C et al. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 970-975.
18. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT983936. Leukemia 2003; 17: 2257-2317. Review.
19. Cragg MS, Bayne MB, Tuft AL, French RR, Beers S, Glennie MJ et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004; 104: 2540-2542. E-pub 22 June 2004.
20. Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ. Apparent modulation of CD20 by rituximab: An alternative explanation. Blood 2004; 103: 3989-3990.
21. Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003; 102: 3514-3520. E-pub 31 July 2003.
22. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2247.
23. Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006-2014.